Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Delivery of peptides for inducing voiding associated with neurological retention

    SBC: Dignify Therapeutics LLC            Topic: 106

    Abstract Neurological conditions such as multiple sclerosis Parkinson s disease dementia spina bifida diabetes stroke and spinal cord injury SCI can result in loss of voluntary voiding of urine and require intermittent bladder catheterization for voiding Catheter use is associated with increased incidence of health problems predominately repeated urinary tract infections sepsis ureth ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter BioSphincter to Treat Fecal Incontinence

    SBC: CELLF-BIO, LLC            Topic: 300

    DESCRIPTION provided by applicant We propose to bring to market a novel regenerative medicine based therapy for fecal incontinence FI FI is the recurrent uncontrolled passage of fecal material The Internal Anal Sphincter IAS is responsible for maintaining anorectal continence Function of the IAS is dependent upon the neuromuscular integrity of both the smooth muscle and the intrinsic en ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GENECAPTURE            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  5. Innovative Mitigation of Radiation Effects in Advanced Technology Nodes

    SBC: Reliable MicroSystems, LLC            Topic: DTRA16A003

    Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  6. Macromolecule Crystallization Screening Results Analysis

    SBC: IXPRESSGENES, INC.            Topic: 100

    Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. New Class of Bright Sharp Tunable Near Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: R

    DESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells Dyes used for FC typically exhibit broad fluorescent emission bands with full width at half maximum fwhm values of nm This limits the maximum numbe ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. New generation of catheters for treatment of atrial fibrillation

    SBC: NOCTURNAL PRODUCT DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Atrial fibrillation AF remains the most commonly occurring cardiac arrhythmia It is associated with a lower quality of life and a higher rate of morbidity andamp mortality primarily due to poor hemodynamics and often stroke One of the main options to treat atrial fibrillation is to ablate abnormal sources of electrical activity using percutaneous radiofrequ ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer s therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD occurs in one out of eight Americans of age and affects of the elderly over Current FDA approved drugs provide short term symptomatic relief of AD There is a pressing need to discover new disease modifying medications AD is multifactorial in origin and progression A drug attenuating several underlying factors is a p ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government